SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token is trending as community members rally behind the token's potential within the Ethereum ecosystem, citing a long-term prophecy and strong community support. Social media buzz suggests growing confidence and anticipation for significant expansion, with some drawing comparisons to other successful meme coins. The community emphasizes the token's role in the broader ETH narrative, attracting attention from traders.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as the community discusses its high throughput and compliance-first architecture, positioning it as a potential infrastructure layer for global finance. Community members highlight its capabilities in handling transactions and its integration with a major fiat anchor. This makes Keeta an infrastructure play that complements existing ecosystems.

Pieverse

PIEVERSE is trending amid community discussion of potential short squeezes and liquidations, particularly in relation to Bitcoin's movements. Sentiment is further influenced by reports of scam concerns and observed trading bot activity, with some traders noting unusual volume and funding rate fluctuations.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members discuss its potential, focusing on transaction speeds and scalability. Some investors are weighing Solana against emerging infrastructure plays like Keeta, which emphasizes compliance and interoperability. Additionally, meme coins on the Solana network, like PMV and WAGMI, are generating buzz and community engagement.

BlackRock Institutional Trust Company N.A. - iShares MSCI India ETF

iShares MSCI India ETF

The iShares MSCI India ETF ($INDA) is trending due to a mix of factors, including large investments from companies like Microsoft, AI developments, and trade-related discussions between the U.S. and India. Community members are weighing potential tariff impacts and analyzing technical indicators, while some suggest India may be a more attractive investment relative to China.

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Lantheus Holdings Inc

Lantheus Holdings is trending due to a recent analyst upgrade from Truist Securities and positive sentiment around the company's potential acquisition targets, particularly Radiopharm Theranostics (RADX). Community discussions highlight LNTH's bullish momentum, potential for a buyout, and the company's strategic positioning in the radiopharmaceutical space with upcoming catalysts.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending due to discussions around rate cut expectations and potential impacts on small-cap companies, with some traders pointing to a rotation into small caps. Community members are actively debating potential breakout levels and whether the recent strength is sustainable, especially with upcoming economic data releases and Federal Reserve decisions on the horizon. There are also discussions around technical patterns and identifying key support and resistance levels for potential trades.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending as the community discusses its potential amid recent market fluctuations, with some viewing dips as buying opportunities while others express concern over stagnation. Talk centers on potential catalysts like tokenization and the impact of macroeconomic factors, including quantitative easing and interest rate policies. Additionally, some are highlighting layer-1 alternatives like Keeta, sparking debates about Ethereum's long-term dominance.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is gaining traction as community members rally around the project's potential and positive outlook, particularly within the Solana ecosystem. Discussions highlight the coin's strong community, locked liquidity, and long-term vision. The 

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders debate its effectiveness as a hedge and its correlation to the VIX, especially given recent market conditions and upcoming economic events like potential interest rate adjustments from the Federal Reserve and Bank of Japan. Community members are actively discussing potential market manipulation and the impact of these factors on UVIX's price, with some expressing frustration over its performance. The broader conversation includes concerns about overvalued markets, potential economic downturns, and geopolitical risks, influencing speculative positioning in volatility-linked instruments.

statis crypto Watchlist

Bitcoin

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Aptevo Therapeutics (APVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Aptevo Therapeutics (APVO) announced on Tuesday that a 100% remission rate was observed in a cohort of its Phase 1b/2 trial evaluating Mipletamig, in combination with Venetoclax and Azacitidine for newly diagnosed patients with acute myeloid leukemia (AML).The <a target="_blank" rel="noopener noreferrer nofollow" href="https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/mipletamig-delivers-100-remission-rate-cohort-3-rainier-trial">study</a> enrolled patients unfit for intensive chemotherapy. No dose-limiting toxicities or cytokine release syndrome were observed in the trial or among any frontline patients treated with Mipletamig to date, the company said.The 100% remission rate achieved at the highest dose level of the trial demonstrated the drug’s potential to redefine the frontline treatment landscape for newly diagnosed AML patients who are unfit for intensive chemotherapy, the company said. It added that 40% of treated patients achieved minimal residual disease (MRD)-negative status, a critical marker of remission.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/APVO">APVO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels. Shares of the company traded 8% higher at the time of writing.<figure class="image"><img style="aspect-ratio:573/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_2_26_05_PM_png_6c3f4781c1.webp" alt="APVO's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="573" height="61"><figcaption>APVO's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed concerns about a potential dip in the share price.<stembedurl>https://stocktwits.com/WEL16/message/628866258</stembedurl>Another highlighted the drop in share price after the initial jump following the news.&nbsp;<stembedurl>https://stocktwits.com/Avior68/message/628866230</stembedurl>The company said that it is actively enrolling patients for the next cohort at the next dose levels and will present current findings at a medical conference in the last quarter.APVO stock is down by 98% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-fda-alleges-novo-nordisk-video-on-weight-loss-drugs-featuring-oprah-winfrey-is-false-or-misleading/chwyFEyRdzF">US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Aptevo Therapeutics Stock Rallies On 100% Remission Rate In Acute Myeloid Leukemia Trial Cohort

The company stated that the 100% remission rate achieved at the highest dose level of the trial demonstrated the drug’s potential to redefine the frontline treatment landscape for newly diagnosed AML patients who are unfit for intensive chemotherapy.

Equity

Shares of Aptevo Therapeutics Inc. (APVO) rocketed 41% on Thursday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-therapeutics-21-million-registered-direct-offering-and">said</a> it is looking to raise about $2.1 million in a registered direct offering and warrants sale.The company said it has entered into definitive securities purchase agreements for the purchase and sale of 1.76 million shares of its common stock in a registered direct offering and warrants to purchase up to 3.5 million shares of common stock in a concurrent private placement at a combined purchase price of $1.19 per share and accompanying warrant.The warrants will have an exercise price of $1.19 per share and will expire five years from the initial exercise date.The offering is expected to close on or about April 4.The company will use the net proceeds from the offering for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.On Stocktwits, retail investor sentiment about Aptevo jumped from ‘extremely bearish’ to ‘extremely bullish’ territory (97/100), hitting a one-year high. At the same time, message volume touched ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:652/153;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_03_at_11_35_45_AM_png_96a7494386.webp" alt="https://stocktwits.com/news-articles/markets/equity/trump-liberation-day-impact-steel-stocks-tumble-with-broader-market/chf7RL4RbeK" width="652" height="153"><figcaption>APVO's Sentiment Meter and Message Volume as of 11:35 a.m. ET on April 3, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the registered direct offering may be a “bailout” to institutions who were short.&nbsp;<stembedurl>https://stocktwits.com/leon_dedrick/message/610264441</stembedurl>Another user, however, expressed optimism about the share price rising to $3.<stembedurl>https://stocktwits.com/Bulltacos/message/610259261</stembedurl><a href="https://stocktwits.com/symbol/APVO">APVO shares</a> have lost over 55% this year and nearly all its value over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-liberation-day-impact-steel-stocks-tumble-with-broader-market/chf7RL4RbeK">Trump’s Liberation Day Impact – Steel Stocks Tumble With Broader Market, UBS Flags Tariffs As 'Incremental Negative' For These Companies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail  Sentiment Touches Year-High

The company said that net proceeds from the offering will be used for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.

Aptevo Therapeutics Inc. shares surged nearly 50% early Thursday on promising leukemia trial results, before paring gains in volatile trading.&nbsp;The stock drew significant heavy interest on Stocktwits, reaching the top 15 trending symbols list, where sentiment turned ‘extremely bullish’ amid a sharp rise in message volume.<figure class="image"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/APVO_sentiment_and_message_volume_on_Dec_12_f6c2ca53dd.png" alt="APVO sentiment and message volume on Dec 12.png" width="1314" height="320"><figcaption>APVO sentiment and message volume on Dec 12 as of 11:45 am ET | source: Stocktwits</figcaption></figure>The company announced that all patients with acute myeloid leukemia (AML) treated with its lead candidate, mipletamig, achieved remission within 30 days in a Phase 1b trial.&nbsp;This includes two patients who experienced complete remission with 100% cancer cell elimination.&nbsp;The trial is exploring mipletamig as frontline therapy in combination with venetoclax and azacitidine, the current standard of care for AML.Retail traders speculated heavily on the stock’s movements, attributing volatility to its small public float of around 500,000 shares.&nbsp;Optimistic users expressed confidence in the company’s long-term potential, with one noting that they had bought 1,000 shares of Aptevo.Aptevo’s oncology pipeline targets aggressive forms of cancer. Other highlights include:• ALG.APV-527: Currently in Phase 1 for 5T4-expressing solid tumors like breast, colon, and non-small cell lung cancers. Preliminary data presented at leading oncology conferences has been positive.• Other preclinical candidates, including APVO711 (immune checkpoint blockade and activator) and APVO603 (dual co-stimulatory solid tumor targeting), are designed for precision cancer treatments.Aptevo stock remains down over 96% year-to-date, reflecting other ongoing challenges. Its current market cap is just over $5 million.Still, retail investors remain cautiously optimistic for now as the company builds on promising clinical data while addressing broader market pressures.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aptevo Therapeutics Stock Draws Retail Attention After Leukemia Trial Data: Retail Extremely Bullish

The company announced that all patients with acute myeloid leukemia treated with its lead candidate, mipletamig, achieved remission within 30 days in a Phase 1b trial.

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

APVO
Aptevo Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest APVO News

APVOAptevo Therapeutics Inc